Introduction {#Sec1}
============

Asthma treatment guidelines are well established \[[@CR1]\], yet many patients with asthma continue to experience persistent symptoms and poor disease control \[[@CR2], [@CR3]\]. Poorly controlled asthma is also often associated with lifestyle limitations, negative psychological and social effects, and a reduced quality of life (QoL) \[[@CR2]--[@CR4]\]. Similarly, available therapies for patients with chronic obstructive pulmonary disease (COPD) are often only partially effective, and patients can remain symptomatic and experience a considerable impact of the disease on their daily activities and health-related (HR)QoL \[[@CR5]\].

The first-choice route of administering medication to manage asthma \[[@CR1], [@CR4]\] and COPD \[[@CR6], [@CR7]\] is inhalation. Many types of devices are available for the delivery of inhaled drugs \[[@CR8]\]; however, studies have shown that \~ 32--89% of patients do not use their inhaler correctly \[[@CR9]--[@CR14]\]. A similar rate of inhaler technique errors occurs for patients with asthma or COPD \[[@CR15]\]. Correct inhaler technique is important because inhaler misuse is associated with insufficient disease control and poor patient outcomes \[[@CR16]\], such as an increased risk of hospitalization due to an asthma exacerbation. Patient preference is an important factor when choosing an inhaler device, because a greater level of satisfaction is related to improved outcomes. Conversely, dissatisfaction with an inhaler and difficulties using it can contribute to poor adherence \[[@CR17]\].

Randomized controlled trials typically train participants in the optimal use of their inhaler and require demonstration of effective use throughout the trial with close monitoring \[[@CR18]\], which may not reflect the situation in real-world clinical practice. Therefore, a need exists for real-world studies in patients with asthma and COPD, to examine how different inhaler devices compare in terms of training, the level of education required for use, ease of use, patient and physician satisfaction, and clinical effectiveness.

Real-world studies can highlight interactions between patient characteristics, preferences, and lifestyle and treatment outcomes that may be missing from randomized controlled trials due to strict exclusion criteria \[[@CR18]\]. They also permit exploration of how these may differ between therapies, and also allow evaluation of clinical outcomes that may be underpowered in randomized controlled trials because of their short duration and strict and idealized patient selection criteria \[[@CR18]\]. For these reasons, regulatory bodies and other organizations such as the European Medicines Agency, United States Food and Drug Administration, and United Kingdom National Institute for Health and Care Excellence are increasingly recognizing the value of real-world evidence to inform decision-making \[[@CR19]--[@CR21]\] and complement evidence from randomized controlled trials.

Budesonide/formoterol fumarate (B/F) Easyhaler^®^ (Orion Pharma, Espoo, Finland) is a multidose dry powder inhaler containing a combination of the inhaled corticosteroid, budesonide, and the long-acting β2-adrenergic agonist, formoterol fumarate, indicated for the treatment of adults with COPD and/or asthma, and adolescents aged 12--17 years with asthma \[[@CR22]\], and approved in several European countries. Two non-randomized, open-label, single-arm studies conducted in Poland and Hungary have confirmed the effectiveness of the B/F Easyhaler for the treatment of asthma \[[@CR23]\], COPD, and asthma-COPD overlap (ACO) \[[@CR24]\] in everyday clinical practice. In the latter study, 30.4% of patients were inhaler-naïve and 69.6% switched to the B/F Easyhaler from other inhalers; after 12 weeks of treatment, significant improvements in lung function, disease control, and HRQoL (all *p* ≤ 0.002) were observed in both inhaler-naive patients and switchers \[[@CR24]\]. However, neither study stratified by prior treatment, precluding comparisons of the effect of switching from specific inhaler devices to the B/F Easyhaler.

Here, we present subgroup analysis of the Hungarian study reported by Tamási et al. \[[@CR24]\]. In the present analyses, patients were stratified by inhaler device used at baseline to confirm the real-world clinical benefits of the B/F Easyhaler in patients with asthma or COPD, and to compare measures of clinical effectiveness, HRQoL, and patient satisfaction associated with the B/F Easyhaler versus the patient's prior inhaler device.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This was a post hoc subanalysis of a 12-week, real-world, multicenter, open-label, non-randomized, non-interventional, single-arm study, conducted across 200 Hungarian centers between May 1, 2016 and December 31, 2017 (National Pharmaceutical Institute of Pharmacy and Nutrition of Hungary; trial registration number: OGYÉI/13942-5/2016) \[[@CR24]\]. The study consisted of three visits and assessed treatment effectiveness in patients diagnosed with asthma or COPD who switched from their current inhaler to B/F Easyhaler. The daily dose and dosing regimen were agreed at visit 1 (baseline, when patients switched to the B/F Easyhaler), in line with the B/F Easyhaler summary of product characteristics \[[@CR16], [@CR17]\]. An optional control visit (visit 2) was offered for study participants to provide additional support prior to assessment of endpoints at 12 weeks (visit 3).

Study Participants {#Sec4}
------------------

Inclusion and exclusion criteria have been previously described \[[@CR24]\]. Eligible patients were ≥ 18 years of age with a diagnosis of asthma or COPD (according to Global Initiative for Asthma \[GINA\] \[[@CR1]\] or Global Initiative for Chronic Obstructive Lung Disease therapeutic guidelines \[[@CR7]\]), and without an exacerbation in the 4 weeks before enrollment. Patients were excluded if they had a hypersensitivity to the study medication or excipients, or were pregnant or breastfeeding. For the subanalyses, patients with ACO and those who were inhaler-naïve were also excluded in order to focus on those who switched their inhaler. The study was approved by the Medical Research Council, Scientific and Research Ethics Committee of Hungary and all procedures followed their ethical standards, as well as those of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all study participants prior to study commencement.

Endpoints {#Sec5}
---------

Study endpoints have been described in detail elsewhere \[[@CR24]\]. In brief, the primary endpoint was change in patient-reported outcome measures after 12 weeks of B/F Easyhaler treatment, comprising the Asthma Control Test (ACT; asthma categorized according to GINA 2018 guidelines \[[@CR1]\] and scored as very poorly controlled (≤ 15), not well controlled \[[@CR16]--[@CR19]\], or well controlled (≥ 20)) \[[@CR25]\] and mini-Asthma Quality of Life Questionnaire (mini-AQLQ; a score \< 4 indicates very limited daily life due to asthma) \[[@CR26]\] for patients with asthma, and the COPD Assessment Test (CAT; a score \> 20 indicates a high impact of COPD on daily life) \[[@CR27]\] and modified Medical Research Council dyspnea scale (mMRC; a score \> 1 indicates difficulty in walking due to breathlessness) \[[@CR28]\] for patients with COPD.

Secondary endpoints assessed disease control at each visit (using the ACT or CAT), health-related quality of life (HRQoL; using the mini-AQLQ and mMRC) and forced expiratory volume in 1 s (FEV~1~; via spirometry according to the American Thoracic Society/European Respiratory Society task force guidelines \[[@CR29]\] and expressed as FEV~1~ % predicted normal). Patient satisfaction with their previous inhaler and the (B/F) Easyhaler was assessed at visits 1 and 3, respectively, using closed questions scored on a six-point scale (where 1 = very good and 6 = unsatisfactory) \[[@CR24]\]. The length of time taken to teach the patient how to use the B/F Easyhaler was also assessed at visit 1 by the clinician.

Statistical Analyses {#Sec6}
--------------------

All data were expressed as percentages or mean (standard deviation \[SD\]). Wilcoxon's signed rank test was used to compare change from baseline for categorical variables and linear mixed model for continuous variables, with a *p* value \< 0.05 considered statistically significant. To limit the number of inhalers compared, only those used by ≥ 10% of patients at baseline were included in the analyses. All statistical analyses were performed using statistical analysis software (SAS)^®^, version 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

Patients {#Sec8}
--------

Patient demographics and baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. In total, 398 and 563 patients with asthma or COPD, respectively, were included. Patients with asthma were younger than those with COPD (mean age: 53.9 versus 64.7 years), and a greater proportion were female (71.0 vs. 51.4%), had received education beyond primary or high school (16.2 vs. 6.0%), had never smoked (74.4 vs. 17.3%), and had better pulmonary function (76.4 vs. 49.9% FEV1% predicted). At baseline, about two-thirds of patients with asthma had poorly controlled disease and impaired daily life, and equally often those with COPD experienced a high-to-medium-high impact on their daily life and difficulty in walking, because of their symptoms.Table 1Patient demographics and baseline characteristics (*n* = 961)ParameterPatients with asthma (*n* = 398)Patients with COPD (*n* = 563)Age (years), mean (SD)53.9 (15.8)64.7 (9.6)Gender (female), *n* (%)282 (71.0)^a^289 (51.4)^b^Height (cm), mean (SD)165 (13.3)165 (11.2)Weight (kg), mean (SD)77 (18.3)75 (19.9)Education, *n* (%) Primary school99 (25.1)294 (52.3) High school232 (58.7)234 (41.6) University or college degree64 (16.2)34 (6.0)Smoking status, *n* (%) Current smoker51 (12.8)256 (45.6) Former smoker51 (12.8)209 (37.2) Never smoked296 (74.4)97 (17.3)HRQoL Mini-AQLQ, mean (SD)3.8 (0.9)n/a mMRC dyspnea scale, mean (SD)n/a2.0 (0.9)Disease control ACT score, mean (SD)14.2 (4.2)n/a CAT score, mean (SD)n/a24.4 (5.8)Lung function, mean (SD) FEV~1~ % predicted76.4 (19.1)49.9 (16.4)*ACT* Asthma Control Test, *AQLQ* Asthma Quality of Life Questionnaire, *CAT* COPD Assessment Test, *COPD* chronic obstructive pulmonary disease, *FEV*~1~ forced expiratory volume in one second, *HRQoL* health-related quality of life, *mMRC* modified Medical Research Council dyspnea scale, *SD* standard deviation^a,b^Patients with missing data were excluded from percentage calculations

The most commonly used inhalers (reported by ≥ 10% of patients before switching to the B/F Easyhaler) were the metered-dose inhaler (MDI), Symbicort Turbuhaler^®^ (AstraZeneca), and DISKUS^®^ (GlaxoSmithKline) among patients with asthma, and the Respimat^®^ (Boehringer Ingelheim), Symbicort Turbuhaler, MDI, Breezhaler^®^ (Novartis) and DISKUS among patients with COPD (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Prior individual inhaler use in patients with **a** asthma (*n* = 398) or **b** COPD (*n* = 563) who switched to the B/F Easyhaler.*Grey shading* denotes the most commonly used inhalers in each disease cohort (those reported by ≥ 10% of patients). *B/F* budesonide/formoterol fumarate, *COPD* chronic obstructive pulmonary disease, *MDI* metered-dose inhaler

Effect on Symptoms, Disease Control, HRQoL, and Pulmonary Function after Switching to the B/F Easyhaler {#Sec9}
-------------------------------------------------------------------------------------------------------

Compared with baseline, patients with asthma and COPD experienced significant improvements in disease symptoms (as measured by ACT and CAT), HRQoL (based on mAQLQ and mMRC) and lung function tests after 12 weeks of B/F Easyhaler treatment, irrespective of prior inhaler type used (*p* \< 0.0001 for all comparisons among the most commonly used inhalers) (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}, respectively). Although patient numbers were too low to calculate statistical significance, numerical improvements from baseline in patients' reported outcomes and FEV~1~ % predicted were also noted with a switch from all other less frequently used inhaler types (Supplementary Tables S1 and S2). Exceptions were observed for lung function after switching from Breezhaler in patients with asthma, and patient-reported outcomes and lung function after switching from Axahaler^®^ (Laboratoires SMB) in patients with COPD.Fig. 2Assessment of switch to B/F Easyhaler combination therapy on changes in patient-reported outcomes and spirometry in patients with asthma (*n* = 310). \**p* \< 0.0001 visit 1 versus visit 3. All values are mean ± standard deviation. Analyses were performed on the most commonly used inhalers in each disease cohort (those reported by ≥ 10% of patients). *ACT* Asthma Control Test, *B/F* budesonide/formoterol fumarate, *EH* Easyhaler, *FEV*~*1*~ forced expiratory volume in 1 s, *mAQLQ* mini-Asthma Quality of Life Questionnaire, *MDI* metered-dose inhalerFig. 3Assessment of switch to B/F Easyhaler combination therapy on changes in patient-reported outcomes and spirometry in patients with COPD (*n* = 435). \**p* \< 0.0001 visit 1 versus visit 3. All values are mean ± standard deviation. Analyses were performed on the most commonly used inhalers in each disease cohort (those reported by ≥ 10% of patients). *B/F* budesonide/formoterol fumarate, *CAT* COPD Assessment Test, *COPD* chronic obstructive pulmonary disease, *EH* Easyhaler, *FEV*~*1*~ forced expiratory volume in 1 s, *MDI* metered-dose inhaler, *mMRC* modified Medical Research Council dyspnea scale

Overall, 12 weeks of treatment with the B/F Easyhaler led to significant improvements in asthma and COPD control (*p* \< 0.0001, respectively) (Fig. [4](#Fig4){ref-type="fig"}). At visit 3, over three-quarters (78%) of patients with asthma had well-controlled disease (ACT score ≥ 20) versus 13% at baseline, and over two-thirds of patients (68%) with COPD experienced a medium-to-low impact of the disease (CAT score ≤ 20) on their daily life and physical functioning (versus 24% at baseline).Fig. 4Effect of switching to B/F Easyhaler combination therapy on disease control in patients with asthma (*n* = 398) or COPD (*n* = 563), assessed using the ACT or CAT, respectively. *ACT* Asthma Control Test, *B/F* budesonide/formoterol fumarate, *CAT* COPD Assessment Test, *COPD* chronic obstructive pulmonary disease. *p* \< 0.0001 (visit 1 versus visit 3) for both asthma and COPD comparisons

Patient and Clinician Perspectives of B/F Easyhaler and Prior Inhaler Use {#Sec10}
-------------------------------------------------------------------------

After 12 weeks of treatment, patient satisfaction with the B/F Easyhaler was significantly (*p* \< 0.0001) greater than with their prior inhaler (among the most commonly used inhalers) for both patients with asthma or COPD (Fig. [5](#Fig5){ref-type="fig"}). In total, 82--86% of patients with asthma rated their satisfaction with the B/F Easyhaler as good or very good, compared with 11, 17, and 18% when using the MDI, DISKUS, or Turbuhaler devices, respectively. Similarly, good or very good satisfaction rates with the B/F Easyhaler were reported by 58--72% of patients with COPD, compared with 9--23% when using prior inhaler devices.Fig. 5Effect of switching to B/F Easyhaler combination therapy on patient satisfaction in patients with **a** asthma (*n* = 310) or **b** COPD (*n* = 435). Analyses were performed on the most commonly used inhalers in each disease cohort (those reported by ≥ 10% of patients).*p* \< 0.0001 (visit 1 versus visit 3) in all comparisons. *B/F* budesonide/formoterol fumarate, *COPD* chronic obstructive pulmonary disease, *MDI* metered-dose inhaler

Clinicians were able to teach correct use of the B/F Easyhaler within 5 min to 82.9 and 69.5% patients with asthma and COPD, respectively; within 10 min, 98.7 and 98.4% of patients with asthma and COPD had learned how to use the device (Table [2](#Tab2){ref-type="table"}). The longer time required for mastering the Easyhaler usage among the patients with COPD may have been affected by their older age compared to the patients with asthma.Table 2Clinician-reported length of time required to teach patients with asthma (*n* = 392) or COPD (*n* = 561) to use the B/F EasyhalerTime required (minutes)Patients with asthma, *n* (%)Patients with COPD, *n* (%) \< 5325 (82.9)390 (69.5)5--1062 (15.8)162 (28.9)10--205 (1.3)9 (1.6)*B/F* budesonide/formoterol fumarate, *COPD* chronic obstructive pulmonary disease

Discussion {#Sec11}
==========

In this subgroup analysis, patients with asthma or COPD who switched to the B/F Easyhaler from their previous inhaler device due to lack of disease control achieved significant improvements within 12 weeks of real-world use in symptoms, disease control, HRQoL, lung function, and patient satisfaction. These findings support and build on those of the primary study in patients with asthma, COPD, or ACO \[[@CR24]\], which found disease to be well controlled after patients switched to the B/F Easyhaler. In the primary analyses, significant benefits in patient-reported outcomes and lung function, and clear improvements in patient satisfaction were also reported, but the study did not directly compare the B/F Easyhaler with specific prior inhaler devices. Another recent real-world, non-interventional, single-arm study in Swedish patients with asthma who switched from the Turbuhaler to the B/F Easyhaler demonstrated that asthma control and lung function were maintained after switching, with most patients obtaining good or complete asthma control (statistically significant; *p* ≤ 0.001) over the 12-week treatment period \[[@CR30]\]. Such comparative information from the present and Swedish studies can be helpful for guiding prescribing practice and switching of treatment for asthma and COPD, and provides reassurance and confidence to clinicians and patients that switching, for example when disease is poorly controlled, should be viewed as an appropriate and potentially beneficial treatment option.

Aerosol inhalation is considered the primary route of administering medication to manage asthma \[[@CR1], [@CR4]\] and other obstructive airway diseases \[[@CR6], [@CR7]\]. However, correct inhaler use is often suboptimal in patients with obstructive airway disease, resulting in reduced therapeutic benefit \[[@CR6], [@CR12]\]. In particular, patients who are older, have underlying pulmonary symptoms, and/or who have received less education and training regarding correct use of their specific device can experience difficulty with achieving correct inhalation technique \[[@CR12], [@CR14], [@CR31], [@CR32]\]. Good inhaler competence appears to be a contributor to the beneficial outcomes and rates of patient satisfaction achieved with the B/F Easyhaler in the present study of older patients with asthma or COPD. As in the primary study, instructing patients on the correct use of the B/F Easyhaler was straightforward, and most clinicians were able to achieve this within 5 min in this patient population who were mainly educated to a primary or high school level. This observation is in line with previous reports supporting that the Easyhaler is simple to teach and use, and associated with high rates of user satisfaction \[[@CR17], [@CR33], [@CR34]\]. Suboptimal inhaler use may result in patients being unable to achieve an inspiratory flow rate strong enough to deliver sufficient bronchodilator medication to the lungs, and this is of particular concern in elderly patients, children, and those with severe airflow limitation \[[@CR35]\]. A pooled analysis of two randomized, multicenter, crossover, open-label studies in patients aged 6--88 years with asthma (*n* = 287) or COPD (*n* = 96) found that by using the Easyhaler, most could achieve or exceed a peak inspiratory flow rate of 30 l/min, which is the minimum required to ensure optimal and consistent dose delivery \[[@CR36]\]. Recent dose uniformity analyses also confirmed consistent delivered dose using the Easyhaler under simulated real-world conditions and a variety of inspiratory flow rates \[[@CR37]\].

A strength of this real-world study was that it included a representative population of patients with asthma or COPD who switched inhaler therapy in everyday clinical practice; however, it had a number of limitations. Satisfaction rates may have been biased because patients switching to the B/F Easyhaler were likely doing so because of uncontrolled disease, and therefore may have been dissatisfied with their prior inhaler. No information on baseline education on inhaler training and adherence data were available for the specific prior inhalers, to enable comparison with the B/F Easyhaler. Patient adherence may have also been influenced by their participation in a clinical trial and inhaler training given (albeit under real-world conditions). The study was limited to 12-week follow-up without a comparator arm.

Currently, few studies exist that describe real-world patient-reported outcomes data for the B/F Easyhaler, or the effects of inhaler switching in patients with COPD (most studies are conducted in patients with asthma); this highlights the need for further real-world studies in switching and in this specific patient population, to inform patients on the possible benefits and how to achieve better adherence and disease control when switching between inhaler devices.

Conclusions {#Sec12}
===========

This subanalysis demonstrated that a switch to the B/F Easyhaler was accompanied by significant benefits in symptoms, disease control, HRQoL, lung function, and patient satisfaction in patients with asthma or COPD in real-world clinical practice. As a next step, these findings should be confirmed in other populations where the B/F Easyhaler is approved for use to investigate whether country-specific differences in patient demographics and characteristics and/or healthcare systems may exist, which might influence inhaler usage and/or the tendency to switch inhalers. Future studies should also assess whether the improved clinical effectiveness, and associated patient adherence and satisfaction, with the B/F Easyhaler is maintained over the long term.
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